3.20
+0.47(+17.22%)
Currency In USD
Address
15 Cushing
Irvine, CA 92618
United States of America
Phone
949 409 7600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
December 30, 2015
| Name | Title | Pay | Year Born |
| Mr. Joshua Riggs | President, Chief Executive Officer & Director | 576,368 | 1983 |
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. & President of Biotime,Inc. | 0 | 1953 |
| Mr. James Liu | Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer | 280,627 | 1996 |
| Ms. Andrea Susan James | Chief Financial Officer | 405,804 | 1982 |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer | 552,014 | N/A |
| Mr. Yuh-Min Chiang Ph.D. | Chief Technology Officer | 0 | N/A |
| Mr. Peter Hong | Vice President, General Counsel & Secretary | 0 | N/A |
| Ms. Sandra O'Donald | Senior Vice President of Business Operations | 0 | N/A |
| Dr. Paul R. Billings FACP, M.D. | Consulting Chief Medical Officer | 0 | 1952 |
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
